Discontinuation Plan for 14-Day Hydroxyzine and Temazepam Scripts
Temazepam requires a gradual taper to prevent potentially life-threatening withdrawal reactions, while hydroxyzine can typically be stopped abruptly without significant risk. 1
Temazepam (Benzodiazepine) - Requires Gradual Taper
The FDA explicitly warns that abrupt discontinuation of temazepam after continued use may precipitate acute withdrawal reactions that can be life-threatening, including seizures. 1 After even 14 days of use, physical dependence can develop, necessitating a careful discontinuation strategy.
Recommended Tapering Approach:
- Use a gradual, patient-specific taper plan rather than abrupt cessation 1
- Reduce the dose by approximately 25% every 1-2 weeks as supported by CDC guidelines for benzodiazepine tapering 2
- For a 14-day course, consider extending the taper over 2-4 weeks beyond the initial prescription period
- Use hyperbolic (proportionate) dose reductions rather than linear reductions—this means each reduction should be a percentage of the current dose, not a fixed amount 3, 4
- If withdrawal symptoms emerge (anxiety, insomnia, tremor, tachycardia, agitation), pause the taper or increase back to the previous tolerated dose 1
Practical Example:
If prescribed temazepam 15 mg nightly for 14 days:
- Days 15-21: Reduce to 11.25 mg (25% reduction)
- Days 22-28: Reduce to 7.5 mg (another 25% reduction)
- Days 29-35: Reduce to 3.75 mg or alternate-day dosing
- Then discontinue
Critical Warnings:
Patients taking higher dosages or those with longer durations of use are at increased risk for severe withdrawal reactions. 1 Monitor closely for withdrawal symptoms including anxiety, insomnia, abdominal pain, vomiting, diaphoresis, tremor, and tachycardia 5.
Hydroxyzine (Antihistamine) - Can Be Stopped Abruptly
Hydroxyzine does not cause physical dependence and can typically be discontinued without tapering. 6 As a first-generation antihistamine, it does not carry the same withdrawal risks as benzodiazepines.
Discontinuation Approach:
- Abrupt cessation is generally safe after 14 days of use
- No gradual taper is required from a pharmacological standpoint
- Monitor for return of the original symptoms (anxiety, insomnia, allergic symptoms) that prompted treatment
- Be aware that rebound insomnia may occur but is not a true withdrawal syndrome 5
Important Considerations:
One study found that hydroxyzine 50 mg was used successfully as a transitional agent when withdrawing patients from lorazepam, suggesting it may actually help with benzodiazepine discontinuation rather than requiring its own taper 7. However, the evidence for antihistamines as long-term insomnia treatments is weak 5.
Combined Management Strategy
If both medications were prescribed together, taper the temazepam first while continuing hydroxyzine, then discontinue hydroxyzine. This approach:
- Prioritizes the medication with greater withdrawal risk (temazepam)
- Allows hydroxyzine to potentially mitigate some anxiety during benzodiazepine taper 7
- Avoids the complexity of simultaneous tapers
Monitoring Requirements:
- Follow up at least weekly during the temazepam taper 8
- Screen for withdrawal symptoms at each contact
- Assess for return of original insomnia symptoms
- Consider cognitive-behavioral therapy for insomnia (CBT-I) to improve long-term outcomes and reduce relapse risk 5, 9
Common Pitfalls to Avoid:
- Never abruptly stop temazepam after any duration of regular use—even 14 days warrants a taper 1
- Do not use a fixed linear reduction schedule (e.g., "reduce by 5 mg every week")—use proportionate reductions instead 3, 4
- Avoid prescribing another benzodiazepine as a substitute unless converting to a longer-acting agent like diazepam for a more controlled taper 5
- Do not dismiss patient reports of withdrawal symptoms as "just anxiety"—these are real physiological responses requiring dose adjustment 1
The key principle is that benzodiazepines like temazepam require respect for their dependence potential even after short-term use, while antihistamines like hydroxyzine do not carry the same pharmacological risks for withdrawal. 5, 2, 1